Maraviroc (MVC), a C-C chemokine receptor type five (CCR5) antagonist, was approved as part of combination antiretroviral therapy (cART) in 2007, for use in treatment-experienced adults infected with CCR5tropic HIV-1 [1] . Whilst, with current treatment strategies, such as maternal cART, low rates of mother-to-child transmission (MTCT) have been reported, in high-income countries, breastfeeding is not recommended because of the potential MTCT risk. However, since 2017, European [2] and United States [3] guidelines have acknowledged that some HIV-infected women may wish to breastfeed, and should be given appropriate support in this decision. Whilst data exist describing the transfer of NRTI, NNRTI, and protease inhibitors to breastfed infants [4, 5] , the pharmacokinetics and safety of MVC in lactating women and their breastfed infants have not been reported. Here, we present the first case of MVC in a breastfeeding mother.
A 36-year-old perinatally HIV-1-infected woman received MVC (150 mg twice daily), lamivudine (150 mg twice daily) and lopinavir/ritonavir (400/ 100 mg twice daily). Her plasma HIV-RNA has remained undetectable with a CD4 þ count above 500 cells/ml on this regimen for over a decade.
In 2018, at 38þ4 weeks of gestation, she delivered a healthy girl (2710 g, 49 cm, head circumference 35 cm, APGAR score 10 at 5 min). Standard neonatal chemoprophylaxis with oral zidovudine (4 mg/kg twice daily) for 14 days was given according to German-Austrian guidelines [6] . Although not recommended, breastfeeding was chosen. Exclusive breastfeeding continued until 6 months of age, with complete weaning by 7 months. Clinical and laboratory assessment at 2, 4, and 8 weeks, and 3, 6, 9, and 12 months after birth revealed normal development. Full blood cell count, renal, and liver parameters remained within normal range. HIV-DNA PCR results were consistently negative, and at 12 months of age, an HIV antibody test was negative.
At 5 months postpartum, a 12-h pharmacokinetic sampling of maternal plasma and breastmilk was performed to assess the breastmilk transfer and estimate infant exposure to MVC. After approval by the local ethics committee of the Charit e University Medicine Berlin, the mother gave her informed consent. Paired maternal plasma and breastmilk samples were obtained predose (0 h), and 1, 2, 4, 6, 8, and 12 h following observed dosing. Thirteen days later, one single plasma sample from the still exclusively breastfed infant was obtained during a routine follow-up visit. Samples were frozen at À30 8C until shipment on dry ice to the laboratory (University of Liverpool, UK) for analysis.
Plasma concentrations of MVC were determined by validated liquid chromatography tandem mass spectrometry method as previously described [7] , with a modification for breastmilk. Briefly, the standards and quality control samples were prepared by spiking known concentration of drugs (TRC, Ontario, Canada) into breastmilk (donated by consenting volunteers through the UK Northwest Milkbank with ethics approval) to obtain a calibration curve (range 2.5-2500 ng/ml). MVC stable isotope was used as internal control to minimize matrix effect.
Interday and intraday precision measured at the quality control levels were 5.60% (3.71-6.72) and 3.04% (2.00-4.40), respectively (mean, range). Interday and intraday accuracy were 0.84% (À7.02-6.99) and 3.30% (À2.78 to 10.61), respectively. Mean recovery at all quality control levels was 98.68% (SD, 5.69%).
The plasma MVC pharmacokinetic profile in the mother (Fig. 1 ) was comparable with published data for postpartum women [8] , with full results reported in the legend to Fig. 1 . MVC was undetectable in the single infant sample. A significant breastmilk transfer of MVC was demonstrated, with a milk-to-plasma (M : P) ratio of 0.61, consistent with studies in lactating rats, which indicated that MVC is extensively secreted into rat milk [9] . MVC is licensed for children (2 years and older) weighing at least 10 kg, at a starting dose of 50 mg. Assuming an infant milk intake of 150 ml/kg/day, we estimate a daily MVC ingestion of less than 2 mg in this 6.5 kg infant. Concerns relating to breastmilk exposure of antiretroviral drugs relate to both infant toxicity and the potential for HIV drug resistance to develop, should MTCToccur in the presence of low drug concentrations. Although MVC was not detected in the infant, it should be noted that the lower limit of quantification of the assay (2.5 ng/ml) is above the IC 90 (0.57 ng/ml) [10] ; low, but clinically relevant infant concentrations were possible. Data from a single case must be interpreted with caution and more data regarding MVC in breastfeeding mother-infant pairs are needed.
In conclusion, there is significant penetration of MVC into breastmilk with a M : P ratio of 0.61, but MVC was undetectable in the breastfed infant.
Symptomatic cerebrospinal fluid HIV escape syndrome in a patient on highly active antiretroviral therapy and suppressed plasma viral load
We read with interest the article by Peluso et al. [1] presenting 10 cases of cerebrospinal fluid (CSF)-HIV escape syndrome describing their clinical, laboratory, and imaging findings. We report a case of symptomatic CSF-HIV escape syndrome that shares similar clinical and laboratory findings and discuss the possible overlap of the entity with CD8 þ -cell encephalitis.
A 53-year-old man with a 20-year history of highly active antiretroviral therapy for HIV, presented with a subacute onset of altered mental status and motor weakness. The patient was compliant with medical therapy and had a CD4 þ greater than 300 cells/ml for years. On admission, he had a CD4 þ count of 292 cells/ml and a plasma viral load of 82 copies/ml. Brain MRI demonstrated mild
